CareDx, Inc (CDNA) Stock Forecast
CDNA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.43 / 5 from 7 analysts
- Price target
- $61.67 average of analyst targets
- Upside to target
- −3.6% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $0.07
- 52-week range
- $14.28 – $69.85
CDNA analyst ratings
7 analystsNumber of analysts at each rating.
CDNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CDNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.26 | $0.24 | $0.27 | $0.28 | −8.9% | 6 |
| Current fiscal year (2026) | $1.20 | $1.15 | $1.23 | $0.58 | +106.6% | 6 |
| Next fiscal year (2027) | $1.29 | $1.17 | $1.47 | $1.20 | +7.6% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CDNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $122.0M | $121.2M | $123.5M | +21.9% | 7 |
| Current fiscal year (2026) | $495.1M | $494.6M | $495.7M | +30.4% | 7 |
| Next fiscal year (2027) | $526.0M | $512.0M | $543.0M | +6.2% | 7 |
CDNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CDNA revenue: reported and forecast
CDNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.19 | $0.25 | $0.25 | $0.26 | $0.26 | +35.6% | 5 up · 0 down |
| Current fiscal year (2026) | $0.93 | $1.21 | $1.20 | $1.20 | $1.20 | +28.3% | 5 up · 0 down |
| Next fiscal year (2027) | $1.13 | $1.35 | $1.33 | $1.29 | $1.29 | +13.8% | 4 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CDNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CDNA beat in 11 of 12.
What analysts expect from CDNA
7 analysts cover CareDx; their consensus rating is buy (4.43 on a 1–5 scale, where 5 is a strong buy). The average price target is $61.67, 3.6% below the latest close of $64.00. Analysts expect earnings of $1.20 per share for 2026, +106.6% from a year earlier. For 2027 the average estimate is $1.29 per share on revenue of $526.0 million. CareDx beat the EPS estimate in 11 of the last 12 quarters.
Related: CDNA income statement, CDNA key metrics, CDNA chart. See the CDNA stock overview for the latest quote and news.
CDNA forecast FAQ
What is CareDx's price target?
The average analyst price target for CareDx is $61.67, 3.6% below the latest close of $64.00.
Is CareDx a buy, hold or sell?
Of 7 analysts covering CareDx, 5 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CareDx's EPS forecast?
Analysts forecast $1.20 per share for 2026 (range $1.15 to $1.23); for 2027 the estimate is $1.29.
What is CareDx's revenue forecast?
The average revenue estimate for 2026 is $495.1 million, growth of 30.4%; for 2027 it is $526.0 million.
When does CareDx report earnings?
CareDx is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $0.07.
Does CareDx usually beat earnings estimates?
CareDx reported EPS at or above the analyst estimate in 11 of the last 12 quarters.